Complement receptor 2–mediated targeting of complement inhibitors to sites of complement activation
In a strategy to specifically target complement inhibitors to sites of complement activation and disease, recombinant fusion proteins consisting of a complement inhibitor linked to a C3 binding region of complement receptor (CR) 2 were prepared and characterized. Natural ligands for CR2 are C3 break...
I tiakina i:
| I whakaputaina i: | J Clin Invest |
|---|---|
| Ngā kaituhi matua: | , , , , , |
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
American Society for Clinical Investigation
2003
|
| Ngā marau: | |
| Urunga tuihono: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC161422/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12813023/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI17348 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|